EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Metformin shows anti‐neoplastic properties by inhibition of oxidative phosphorylation and glycolysis in epidermolysis bullosa‐associated aggressive cutaneous squamous cell carcinoma

T Welponer iD, D D Weber, L Trattner, B Tockner, S Aminzadeh-Gohari, V Leb-Reichl, A Kaufmann, R Zauner, M Wimmer, V Wally, T K Felder, D Strunk und 5 weitere

Journal of the European Academy of Dermatology and Venereology · 2024

DOI: 10.1111/jdv.19488 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2024. Verfasst von T Welponer und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, Salzburg, Austria. Hauptthemen laut MEDLINE: Carcinoma, Squamous Cell, Skin Neoplasms, Epidermolysis Bullosa, Epidermolysis Bullosa Dystrophica. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Austrian Science Fund (FWF), DEBRA Austria.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

While most cutaneous squamous cell carcinomas (cSCCs) are treatable, certain high‐risk cSCCs, such as those in recessive dystrophic epidermolysis bullosa (RDEB) patients, are particularly aggressive. Owing to repeated wounding, inflammation and unproductive healing, RDEB patients have a 68% cumulative risk of developing life‐threatening cSCCs by the age of 35, and a 70% risk of death by the age of 45. Despite aggressive treatment, cSCC represents the leading cause of premature mortality in these patients, highlighting an unmet clinical need. Increasing evidence points to a role of altered metabolism in the initiation and maintenance of cSCC, making metabolism a potential therapeutic target.

Objectives

We sought to determine the feasibility of targeting tumour cell energetics as a strategy to selectively hinder the growth advantage of aggressive cSCC.

Methods

We evaluated the cell energetics profiles of RDEB‐SCC cells by analysing available gene expression data against multiple gene signatures and single‐gene targets linked to metabolic reprogramming. Additionally, we employed real‐time metabolic profiling to measure glycolysis and respiration in these cells. Furthermore, we investigated the anti‐neoplastic properties of the metformin against human and murine high‐risk cSCCs in vitro and in vivo.

Results

Gene expression analyses highlighted a divergence in cell energetics profiles between RDEB‐SCC and non‐malignant RDEB keratinocytes, with tumour cells demonstrating enhanced respiration and glycolysis scores. Real‐time metabolic profiling supported these data and additionally highlighted a metabolic plasticity of RDEB‐SCC cells. Against this background, metformin exerted an anti‐neoplastic potential by hampering both respiration and glycolysis, and by inhibiting proliferation in vitro. Metformin treatment in an analogous model of fast‐growing murine cSCC resulted in delayed tumour onset and slower tumour growth, translating to a 29% increase in median overall survival.

Conclusions

Our data indicate that metformin exerts anti‐neoplastic properties in aggressive cSCCs that exhibit high‐risk features by interfering with respiration and glycolytic processes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Squamous CellSkin NeoplasmsEpidermolysis BullosaEpidermolysis Bullosa DystrophicaHumansAnimalsMiceOxidative Phosphorylation

Autor:innen und Institutionen

  • Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, Salzburg, Austria.
  • EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, Salzburg, Austria.
  • Research Program for Receptor Biochemistry and Tumor Metabolism, Department of Pediatrics, University Hospital of the Paracelsus Medical University, Salzburg, Austria.
  • Department of Laboratory Medicine, University Hospital of the Paracelsus Medical University, Salzburg, Austria.
  • Cell Therapy Institute, Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University, Salzburg, Austria.

ORCID-Profile: T Welponer, J Piñon Hofbauer

Förderung

  • Austrian Science Fund (FWF)
  • DEBRA Austria

Zitieren

APA

Welponer, T., Weber, D. D., Trattner, L., Tockner, B., Aminzadeh-Gohari, S., Leb-Reichl, V., Kaufmann, A., Zauner, R., Wimmer, M., Wally, V., Felder, T. K., Strunk, D., Koller, U., Bauer, J. W., Kofler, B., Guttmann-Gruber, C., & Piñon Hofbauer, J. (2024). Metformin shows anti‐neoplastic properties by inhibition of oxidative phosphorylation and glycolysis in epidermolysis bullosa‐associated aggressive cutaneous squamous cell carcinoma. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19488

Vancouver

Welponer T, Weber DD, Trattner L, Tockner B, Aminzadeh-Gohari S, Leb-Reichl V, et al. Metformin shows anti‐neoplastic properties by inhibition of oxidative phosphorylation and glycolysis in epidermolysis bullosa‐associated aggressive cutaneous squamous cell carcinoma. Journal of the European Academy of Dermatology and Venereology. 2024. doi:10.1111/jdv.19488

BibTeX
@article{Welponer2024,
  author = {Welponer, T and Weber, D D and Trattner, L and Tockner, B and Aminzadeh-Gohari, S and Leb-Reichl, V and Kaufmann, A and Zauner, R and Wimmer, M and Wally, V and Felder, T K and Strunk, D and Koller, U and Bauer, J W and Kofler, B and Guttmann-Gruber, C and Piñon Hofbauer, J},
  title = {Metformin shows anti‐neoplastic properties by inhibition of oxidative phosphorylation and glycolysis in epidermolysis bullosa‐associated aggressive cutaneous squamous cell carcinoma},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2024},
  doi = {10.1111/jdv.19488}
}
Kostenlos starten →